Non-interventional Observational Study of Pramipexole in Restless Legs Syndrome: Impact on Quality of Life
Sifrol® (Pramipexole) Impact on RLS Related Quality of Life: A 12-weeks Observational Study in Patients With Primary RLS
Sponsor: Boehringer Ingelheim
A observational or N/A phase clinical study on Restless Legs Syndrome, this trial is completed. The trial is conducted by Boehringer Ingelheim and has accumulated 8 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Nov 2025 — Present [monthly]
Completed
-
Sep 2025 — Nov 2025 [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Feb 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalen, Germany , Aarbergen, Germany , Adendorf, Germany , Aham, Germany , Ahaus, Germany , Ahlen, Germany , Ahorntal, Germany , Aichach, Germany , Aislingen, Germany , Albstadt, Germany and 307 more locations